FDA won't hold companies responsible for independent user content on their social media properties

U.S. pharmaceutical companies may have gotten off easy compared to other areas of the world, said Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA.

The European Court of Justice recently ruled that online remarks about drugs posted by a third party on the manufacturer's Web property could constitute advertising, even though the post's author has no connection with the product's manufacturer or marketer.

“That's carte blanche for an almost complete gag order on anyone who wants to discuss anything to do with medicines,” Pitts said.
Sign Up for Our Email Newsletter

RECENT NEWS

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

From 2000 to 2020, the U.S. saw more than 1,600 hospital mergers. These consolidations have led to decreased competition,...  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?
  • RCJ
  • 05/09/2025 12:00 AM

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?

The principal reason for the disparity in biopharmaceutical pricing is that governments in other developed countries use ...  Read more

DRUGWONKS BLOG